Worg Pharmaceuticals Secures a Hefty 1.1 Billion CNY in Series C Funding, Paving the Way for Allergy Treatment Innovations

Key Takeaways:

  • Worg Pharmaceuticals has raised 1.1 billion CNY ($172 million USD) in its latest Series C funding round.
  • DT Capital Partners and Shanghai Bairun Investment Holding Group led the round, among several other prominent investors.
  • The Hangzhou-based biotech firm is focused on developing novel treatments for allergies and other diseases.
  • To date, Worg Pharmaceuticals has raised a total of 1.7 billion CNY ($266 million USD) across three rounds of funding.

HANGZHOU, ZHEJIANG – It’s a big day for the biotech industry in China and indeed the world, as Worg Pharmaceuticals, the clinical stage biopharmaceutical company, has just secured a staggering 1.1 billion CNY (approx. $172 million USD) in a Series C funding round.

The round, which officially closed today, was led by investment titans DT Capital Partners and Shanghai Bairun Investment Holding Group. Other key participants included Jiansu Ziben, Kangjun Capital, Kequan Fund, and Shanghai Qinda Investment Holding Group. This impressive roster of investors has boosted Worg Pharmaceuticals’ total funding to an impressive 1.7 billion CNY ($266 million USD).

Located in Hangzhou, China, Worg Pharmaceuticals has been making waves in the biotechnology field with its dedication to developing new treatments for allergies and other diseases. This significant new injection of capital promises to bolster the company’s R&D capabilities, enabling it to deepen its research and accelerate the path to commercialization for its innovative treatments.

The company’s profile on Crunchbase offers a detailed view of its funding journey and its investor base, revealing a steady progression of successful fundraising rounds that reflect investor confidence in the firm’s potential.

Explore the bubble  Needle Strikes Gold: AI Marketing Startup Lands $1.2M Pre-Seed Funding Boost

Today’s announcement puts Worg Pharmaceuticals squarely on the map as one of the most watched startups in Asia’s thriving biotech scene. With such robust backing and the sheer potential of its innovative research, all eyes will now be on this Hangzhou powerhouse as it aims to break new ground in allergy and disease treatment.

For further information, you can visit the official website of Worg Pharmaceuticals.

Looking to promote your brand to a targeted audience of startup founders, investors, and C-level executives? Check out our advertising opportunities and sponsored articles at StartupBubble.news! Reach out to us at [email protected] to discuss how we can help amplify your brand’s visibility and drive results. Don’t miss out on this opportunity to connect with our engaged readership. Contact us today!

Explore the bubble  Halodoc Rakes in $100M in Series D Funding, Accelerating Health-Tech Innovation

Startup Bubble News

Startup Bubble News highlights the latest trends, funding rounds, acquisitions, and emerging technologies in the startup ecosystem. Focusing on innovative ventures, it provides insight into disruptive businesses and growth opportunities, offering essential updates for entrepreneurs and investors alike.

Leave a Reply

Your email address will not be published.

Previous Story

Instituto Clima e Sociedade Bags $6M Grant from Bezos Earth Fund in Landmark Climate Action Effort

Next Story

Startup Showcase: Attn: Grace – Redefining Incontinence Care for Women

Latest from Featured Posts